Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Lei Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Salvage Therapy, Protein Kinase Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Hospital Development Center, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
This study aimed to compare the survival outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who underwent or did not undergo salvage surgery followed by a triple combination conversion treatment consisted of locoregional treatment (LRT), tyrosine kinase inhibitors (TKIs), and anti-PD-1 antibodies.
Methods
The data from 93 consecutive patients with initially unresectable HCC and PVTT across 4 medical centers were retrospectively reviewed. They were converted successfully by the triple combination treatment and underwent or did not undergo salvage resection. The baseline characteristics, conversion schemes, conversion treatment-related adverse events (CTRAEs), overall survival (OS), and progression-free survival (PFS) of the salvage surgery and non-surgery groups were compared. Multivariate Cox regression analysis was performed to identify independent risk factors for OS and PFS. Additionally, subgroup survival analysis was conducted by stratification of degree of tumor response and type of PVTT.
Results
Of the 93 patients, 44 underwent salvage surgery, and 49 did not undergo salvage surgery. The OS and PFS of the salvage surgery and non-surgery groups were not significantly different (P = .370 and .334, respectively). The incidence and severity of CTRAEs of the 2 groups were also comparable. Subgroup analyses revealed that for patients with complete response (CR) or types III-IV PVTT, there was a trend toward better survival in patients who did not undergo salvage surgery. Multivariate analysis showed that baseline α-fetoprotein and best tumor response per mRECIST criteria were independent prognostic factors for OS and PFS.
Conclusions
For patients with initially unresectable HCC and PVTT who were successfully converted by the triple combination therapy, salvage liver resection may not be necessary, especially for the patients with CR or types III-IV PVTT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China.
- Department of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital of Fujian Medical University, Fuzhou, People's Republic of China.
- Department of Hepatobiliary Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
- Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, People's Republic of China.
- Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, People's Republic of China.
ORCID-Profile: Shu-Qun Cheng
Förderung
- Shanghai Hospital Development Center
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, L., Feng, J. K., Lu, C. D., Wu, J. Y., Zhou, B., Wang, K., Wei, X. B., Liang, C., Zhou, H. K., Shi, J., Guo, W. X., Lau, W. Y., Yan, M. L., & Cheng, S. Q. (2024). Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The Oncologist. https://doi.org/10.1093/oncolo/oyae032
Vancouver
Wang L, Feng JK, Lu CD, Wu JY, Zhou B, Wang K, et al. Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody. The Oncologist. 2024. doi:10.1093/oncolo/oyae032
BibTeX
@article{Wang2024,
author = {Wang, Lei and Feng, Jin-Kai and Lu, Chong-De and Wu, Jia-Yi and Zhou, Bin and Wang, Kang and Wei, Xu-Biao and Liang, Chao and Zhou, Hong-Kun and Shi, Jie and Guo, Wei-Xing and Lau, Wan Yee and Yan, Mao-Lin and Cheng, Shu-Qun},
title = {Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae032}
}
EUVIMED